February 10, 2025 11:28 AM EST
R&D

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

Lei Lei Wu

News Reporter

Boehringer In­gel­heim said its ex­per­i­men­tal treat­ment for a chron­ic lung dis­ease suc­ceed­ed in a piv­otal study, and it’s tak­ing the re­sults to the FDA to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Trump’s tar­iff im­pact like­ly ‘min­i­mal’ for brand-name drug­mak­ers, man­u­fac­tur­ing part­ners

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times